Epithelioid hemangioendothelioma, an ultra-rare cancer : a consensus paper from the community of experts
Stacchiotti, Silvia (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia))
Miah, Aisha B. (The Royal Marsden Hospital)
Frezza, Anna Maria (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia))
Messiou, Christina (Department of Radiology. The Royal Marsden Hospital and The Institute of Cancer Research)
Morosi, Carlo (Radiology Department. Fondazione IRCCS Istituto Nazionale Tumori)
Caraceni, Augusto (Fondazione IRCCS Istituto Nazionale Tumori)
Antonescu, Cristina (Memorial Sloan Kettering Cancer Center)
Bajpai, Jyoti (Homi Bhabha National Institute. Medical Oncology Department)
Baldini, Elizabeth Healey (Dana-Farber Cancer Center/Brigham)
Bauer, Sebastian (University of Duisburg-Essen)
Biagini, Roberto (Regina Elena National Cancer Institute)
Bielack, Stefan S. (Klinikum Stuttgart - Olgahospital)
Blay, Jean-Yves (Department of Medical Oncology. Centre Leon Berard. Université Claude Bernard Lyon. Unicancer)
Bonvalot, Sylvie (Institut Curie. Department of Surgical Oncology)
Boukovinas, Ioannis P. (Nordix)
Bovee, Judith V.M.G. (Leiden University Medical Center)
Boye, Kjetil (The Norwegian Radium Hospital)
Brodowicz, Thomas (Medical University Vienna)
Callegaro, Dario (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia))
De Álava, Enrique (Department of Normal and Pathological Cytology and Histology. School of Medicine. University of Seville)
Deoras-Sutliff, M. (The EHE Foundation)
Dufresne, Armelle (Department of Medical Oncology. Centre Leon Berard. Université Claude Bernard Lyon. Unicancer)
Eriksson, Mikael (Department of Oncology. Skane University Hospital and Lund University)
Errani, Costantino (Orthopaedic Service. Musculoskeletal Oncology Department. IRCCS Istituto Ortopedico Rizzoli)
Fedenko, Alexander (Medical Oncology Division. P.A. Herzen Cancer Research Institute)
Ferraresi, Virginia (Sarcomas and Rare Tumors Unit. IRCCS Regina Elena National Cancer Institute)
Ferrari, Andrea (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia))
Fletcher, Christopher D.M. (Department of Pathology Brigham & Women's Hospital)
Garcia del Muro, Xavier (Universitat de Barcelona)
Gelderblom, Hans J. (Department of Medical Oncology. Leiden University Medical Center)
Gladdy, Rebecca A. (University of Toronto and Lunenfeld-Tanenbaum Research Institute)
Gouin, François (Department of Surgery. Centre Leon Berard)
Grignani, Giovanni (Candiolo Cancer Institute. FPO - IRCCS)
Gutkovich, J. (NUY Langone Medical Center)
Haas, Rick (Department of Radiotherapy. the Leiden University Medical Center)
Hindi, Nadia (Universidad de Sevilla. Instituto de Biomedicina de Sevilla)
Hohenberger, Peter (Mannheim University Medical Center)
Huang, Paul (Division of Molecular Pathology. The Institute of Cancer Research)
Joensuu, Heikki T. (Department of Oncology. Helsinki University Hospital & Helsinki University)
Jones, Robin Lewis (Department of Cancer. The Royal Marsden Hospital and The Institute of Cancer Research)
Jungels, Christiane (Institut Jules Bordet. Université Libre de Bruxelles)
Kasper, Bernd (University of Heidelberg. Mannheim University Medical Center. Sarcoma Unit)
Kawai, Akira (Musculoskeletal Oncology and Rehabilitation Medicine. Rare Cancer Center National Cancer Center Hospital)
Le Cesne, Axel (International Department. Gustave Roussy)
Le Grange, Franél (UCLH - University College London Hospitals NHS Foundation Trust)
Leithner, Andeas (Department of Orthopaedics and Trauma Medical University Graz)
Leonard, H. (Chair of Trustees of the EHE Rare Cancer Charity (UK). Charity number 1162472)
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau)
Martin Broto, Javier (Hospital Universitario Fundación Jiménez Díaz)
Merimsky, Ofer (Unit of Soft Tissue and Bone Oncology. Division of Oncology. Tel-Aviv Medical Center affiliated with Sackler School of Medicine. Tel Aviv University)
Merriam, Priscilla (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Department of Medical Oncology)
Miceli, Rosalba (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia))
Mir, Olivier (Sarcoma Group. Gustave Roussy)
Molinari, Massimo (University of Pittsburgh Medical Center. Thomas Starzl Transplant Institute)
Montemurro, Michael (Oncology. CHUV Lausanne)
Oldani, Graziano (Division of Abdominal Surgery. University Hospitals of Geneva)
Palmerini, Emanuela (Chemotherapy Unit. IRCCS Istituto Ortopedico Rizzoli)
Pantaleo, Maria Abbondanza. (Division of Oncology. IRCCS Azienda Ospedaliero-Universitaria di Bologna)
Patel, Sapna Pradyuman (Sarcoma Center. The University of Texas M.D. Anderson Cancer Center)
Piperno-Neumann, Sophie (Department of Medical Oncology. Institut Curie)
Raut, Chandrajit Premanand (Dana Farber Cancer Center. Harvard Medical School)
Ravi, Vinod (Sarcoma Center. The University of Texas M.D. Anderson Cancer Center)
Razak, Albiruni Ryan Abdul (Princess Margaret Cancer Centre and Sinai Healthcare System & Faculty of Medicine. University of Toronto)
Reichardt, Peter (Helios Klinikum Berlin-Buch. Department of Oncology and Palliative Care)
Rubin, Brian P. (Robert J. Tomsich Pathology and Laboratory Medicine Institute. Cleveland Clinic)
Rutkowski, Piotr (Maria Sklodowska-Curie National Research Institute of Oncology. Department of Soft Tissue/Bone Sarcoma and Melanoma)
Safwat, Akmal Ahmed (Aarhus University Hospital (Aarhus, Dinamarca))
Sangalli, Claudia (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia))
Sapisochin, Gonzalo (Multi-Organ Transplant and HPB Surgical Oncology. Division of General Surgery. Department of Surgery. University of Toronto)
Sbaraglia, Marta (Department of Pathology. Azienda Ospedaliera Università Padova)
Scheipl, Susanne (Department of Orthopaedics and Trauma. Medical University of Graz)
Schöffski, Patrick (Leuven Cancer Institute)
Strauss, Dirk Cornelius (Department of Surgery. The Royal Marsden Hospital and The Institute of Cancer Research)
Strauss, Sandra J. (University College London Hospital)
Sundby Hall, Kirsten (Department of Oncology. Oslo University Hospital. The Norwegian Radium Hospital)
Tap, William D. (Department of Medicine. Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College)
Trama, Annalisa (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia))
Tweddle, A. (Palliative Care. The Royal Marsden Hospital and The Institute of Cancer Research London)
van der Graaf, Winette T.A. (The Netherlands Cancer Institute (Amsterdam, Països Baixos))
van de Sande, Michiel (Department of Orthopedic Surgery Bone and Soft Tissue Tumor Unit. Leiden University Medical Center)
Van Houdt, Winan (Sarcoma and Melanoma Unit. The Netherlands Cancer Institute)
van Oortmerssen, Gerard (Co-Chair of Sarcoma Patients EuroNet (SPAEN). Woelfersheim. Germany & Chairman of the Dutch organisation for sarcoma patients (Patiëntenplatform Sarcomen). Guest researcher at Leiden University (Leiden Institute for Advanced Computer Science). Leiden University)
Wagner, Andrew J. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Department of Medical Oncology)
Wartenberg, Markus (Chair of the Board of Directors of Sarcoma Patients EuroNet (SPAEN). Sarcoma Patients EuroNet (SPAEN))
Wood, J. (The Royal Marsden NHS Foundation Trust)
Zaffaroni, Nadia (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia))
Zimmermann, Camilla (Department of Supportive Care. Princess Margaret Cancer Centre and Division of Palliative Medicine. Department of Medicine. University of Toronto)
Casali, Paolo Giovanni (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia))
Dei Tos, Angelo (Department of Pathology. Azienda Ospedaliera Università Padova)
Gronchi, Alessandro (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia))

Data:	2021
Resum:	Epithelioid hemangioendothelioma (EHE) is an ultra-rare, translocated, vascular sarcoma. EHE clinical behavior is variable, ranging from that of a low-grade malignancy to that of a high-grade sarcoma and it is marked by a high propensity for systemic involvement. No active systemic agents are currently approved specifically for EHE, which is typically refractory to the antitumor drugs used in sarcomas. The degree of uncertainty in selecting the most appropriate therapy for EHE patients and the lack of guidelines on the clinical management of the disease make the adoption of new treatments inconsistent across the world, resulting in suboptimal outcomes for many EHE patients. To address the shortcoming, a global consensus meeting was organized in December 2020 under the umbrella of the European Society for Medical Oncology (ESMO) involving >80 experts from several disciplines from Europe, North America and Asia, together with a patient representative from the EHE Group, a global, disease-specific patient advocacy group, and Sarcoma Patient EuroNet (SPAEN). The meeting was aimed at defining, by consensus, evidence-based best practices for the optimal approach to primary and metastatic EHE. The consensus achieved during that meeting is the subject of the present publication.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article de revisió ; recerca ; Versió publicada
Matèria:	Sarcoma ; Epithelioid hemangioendothelioma ; Diagnosis ; Treatment ; Management ; Guidelines
Publicat a:	ESMO open, Vol. 6 Núm. 3 (june 2021) , p. 100170, ISSN 2059-7029

DOI: 10.1016/j.esmoop.2021.100170
PMID: 34090171

14 p, 2.6 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats